RhumbLine Advisers
EWTX icon

RhumbLine Advisers’s Edgewise Therapeutics EWTX Stock Holding History

RhumbLine Advisers’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67M Buy
90,232
+6,692
+8% +$231K ﹤0.01% 1623
2026
Q1 		$2.63M Sell
83,540
-1,535
-2% -$44.3K ﹤0.01% 1722
2025
Q4 		$2.11M Sell
85,075
-19,754
-19% -$397K ﹤0.01% 1855
2025
Q3 		$1.7M Sell
104,829
-7,654
-7% -$109K ﹤0.01% 1999
2025
Q2 		$1.47M Buy
112,483
+3,646
+3% +$52.6K ﹤0.01% 2052
2025
Q1 		$2.39M Buy
108,837
+6,440
+6% +$169K ﹤0.01% 1725
2024
Q4 		$2.73M Buy
102,397
+1,525
+2% +$48.6K ﹤0.01% 1724
2024
Q3 		$2.69M Buy
100,872
+2,603
+3% +$51.8K ﹤0.01% 1734
2024
Q2 		$1.77M Buy
98,269
+14,041
+17% +$245K ﹤0.01% 1949
2024
Q1 		$1.54M Buy
84,228
+19,895
+31% +$316K ﹤0.01% 2037
2023
Q4 		$704K Buy
64,333
+723
+1% +$5.08K ﹤0.01% 2473
2023
Q3 		$364K Buy
63,610
+330
+0.5% +$2.24K ﹤0.01% 2817
2023
Q2 		$490K Buy
63,280
+4,949
+8% +$41.7K ﹤0.01% 2699
2023
Q1 		$389K Buy
58,331
+7,341
+14% +$68K ﹤0.01% 2526
2022
Q4 		$456K Buy
50,990
+6,845
+16% +$64.2K ﹤0.01% 2507
2022
Q3 		$434K Buy
44,145
+2,431
+6% +$24.6K ﹤0.01% 2559
2022
Q2 		$332K Buy
41,714
+4,853
+13% +$36.7K ﹤0.01% 2708
2022
Q1 		$358K Buy
36,861
+6,350
+21% +$81.7K ﹤0.01% 2577
2021
Q4 		$466K Buy
+30,511
New +$549K ﹤0.01% 2537

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's EWTX Position: Q2 2026 in Review

RhumbLine Advisers increased its Edgewise Therapeutics (EWTX) stake by 8% in Q2 2026, buying an estimated $231K and bringing the position to 90,232 shares worth $3.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1623.

RhumbLine Advisers first reported a position in EWTX in Q4 2021 and has held it in 19 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • RhumbLine Advisers held 90,232 shares of Edgewise Therapeutics worth $3.67M as of Q2 2026.
  • RhumbLine Advisers bought 6,692 Edgewise Therapeutics shares in Q2 2026, an estimated $231K.
  • Edgewise Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1623 holding.
  • RhumbLine Advisers first reported a position in Edgewise Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.